Who are Open-label rusfertide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eporatio, Mircera, Silapo, Aranesp, Neorecormon, Epogen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/open-label-rusfertide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Open-label rusfertide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-label rusfertide (Open-label rusfertide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoietin receptor agonist. Area: Nephrology.

phase 3 Erythropoietin receptor agonist Erythropoietin receptor Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

Open-label rusfertide (Open-label rusfertide) — Protagonist Therapeutics, Inc.. Rusfertide is a human erythropoietin receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Open-label rusfertide TARGET	Open-label rusfertide	Protagonist Therapeutics, Inc.	phase 3	Erythropoietin receptor agonist	Erythropoietin receptor
Eporatio	EPOETIN THETA		marketed		Erythropoietin receptor	2009-01-01
Mircera	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Hoffman-La Roche	marketed		erythropoietin receptor	2007-01-01
Silapo	EPOETIN ZETA	Hospira UK Limited	marketed		Erythropoietin receptor	2007-01-01
Aranesp	DARBEPOETIN ALFA	Amgen	marketed	Erythropoiesis-stimulating Agent [EPC]	Erythropoietin receptor	2001-01-01
Neorecormon	EPOETIN BETA	Roche Registration Limited	marketed		Erythropoietin receptor	1997-01-01
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoietin receptor agonist class)

Dong-A ST Co., Ltd. · 1 drug in this class
Ministry of Health, Malaysia · 1 drug in this class
Protagonist Therapeutics, Inc. · 1 drug in this class
Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Open-label rusfertide — Competitive Intelligence Brief. https://druglandscape.com/ci/open-label-rusfertide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing